

EMERGING MARKETS: Covid-19 Vaccinations and Challenges

Our Covid-19 vaccination table includes updated information on the immunization strategies selected EMs are pursuing and the challenges they face.

Below are some of the latest developments. Please do not hesitate to contact us if you want to discuss any of the countries mentioned in more detail.

Click on 'View PDF' to see the table.

HIGHLIGHTS

Vaccine rollout

- In Brazil, the Health Ministry is preparing the 2022 vaccination plan, including booster shots for everyone above 18 years
- **Chile** has administered 3.8mn third booster jabs since August; an initial study carried out locally shows that the booster jabs are helping prevent both transmission and hospitalization.
- **Colombia**'s health regulatory agency is expected to give the green light for the vaccination of 3-11 year olds, who total around 4mn people; the Sinovac and Pfizer vaccines would be used for this age cohort.
- **India**'s government is expecting to have administered 1bn vaccinations by mid-Oct, though most of these are first doses; as of 10 Oct, 267.6mn people (19.2% of population) were fully vaccinated.
- Media reports and official statements seem to indicate that vaccine hesitancy is starting to manifest in the Philippines and Indonesia despite these countries still being at the lower end of their vaccine targets.
- In **Peru**, 18 year olds are now eligible for their first vaccine dose in most of the country at the same time as booster jabs begin to be applied to 500,000 health sector workers.
- Vaccination progress in Russia is expected to pick up significantly in the coming few weeks as an increasing number of the country's regions are introducing some form of compulsory vaccination.
- With 30mn (59% of the population) fully and 40mn (78%) partially vaccinated, **South Korea** is on course for its 70% herd immunity goal before November, with high school students now eligible for inoculation.

Vaccine procurement

• India could obtain 1bn Pfizer doses by the end of 2022 provided the two parties can reach an agreement over indemnity clauses and India opts not to rely solely on domestically produced vaccines.

Teneo Macro 1

- Mexico's state-owned vaccine manufacturer Birmex is expected to seal a production and packaging agreement with the Russian Direct Investment Fund (RDIF) that would allow Birmex to make up for delayed deliveries of the Sputnik vaccine; Birmex has capacity to produce 2mn Sputnik doses per month.
- **Nigeria** received a French government donation of 500,000 AstraZeneca vaccines in early October, and the National Primary Health Care Development Agency (NPHCDA) expects a regular COVAX shipment of 3.6mn Pfizer-BioNTech vaccines later this month.
- A total of around 195mn doses has been acquired by South Korea, while SK Bioscience has signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to expand capacity reservations for manufacturing further vaccines.

Infections and new variants

- In **Argentina**, where genomic sequencing capacity is limited, the Delta variant still only accounts for under 10% of cases, though its prevalence has increased rapidly in the last fortnight, and it is expected to be dominant within the next six weeks; travel restrictions and the vaccination campaign help explain why Delta has not spread more quickly.
- The fourth wave of the pandemic is picking up in Poland with the rolling seven-day average of new cases and deaths
 per day increasing by 49% and 39% respectively during the past week. Infection and death levels are expected to surge
 in the coming weeks.
- In total, 9,879 new cases were reported in South Korea in the week to 8 October and have now exceeded 1,000 for 98 consecutive days. With 518 ICU beds immediately available, the government issued an executive order to secure a further 146 critical care beds and over 1,000 beds for less severe cases. The Delta variant accounts for all new cases, with the positivity rate highest among the 30-39 age cohort.

Vaccine diplomacy

- China's vaccine exports fell 21% in August from July in value terms, according to customs data, in a sign that countries that relied on Chinese-made vaccines when they were the only option are now shifting towards Western-made alternatives.
- Bangladesh, Nepal, Myanmar and Iran are among the first beneficiaries of **India**'s recent decision to lift its vaccine export ban, which was put in place in April amid a particularly severe second coronavirus wave.
- Russia is putting diplomatic pressure on the World Health Organization and the European Medicines Agency to approve
 its Sputnik V vaccine.
- South Korea is donating 1.1mn AstraZeneca doses to Vietnam and almost half a million to Thailand. Seoul also approved healthcare aid requests to **North Korea** but border restrictions make the delivery schedule unclear, while the government is also providing 10bn won (USD 8.4mn) for civilian organizations to undertake humanitarian aid to Pyongyang. The WHO has also begun shipping Covid-19 medical supplies to North Korea.

Client Portal >>

Macro Research +44 20 7186 8894 Macro@teneo.com

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.

Teneo Macro 2



Emerging Markets Covid-19 Vaccination Strategies and Challenges

Rating of countries' vaccine rollout (as of 13 October 2021):

Between 0% and 10% of the total population have received at least one Covid-19 vaccine dose Between 10% and 30% of the total population have received at least one Covid-19 vaccine dose More than 30% of the total population have received at least one Covid-19 vaccine dose

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Israel	Israel has been among the most aggressive countries in the world in pushing boosters. In late Oct, the government will begin requiring proof of either a booster or a negative test to enter restaurants, bars, or other indoor entertainment spots. Boosters are required to keep "Green Pass" Covid passports valid. In addition to Pfizer, Moderna is being used for those 18+. A lower dosage of Pfizer has been authorized for vulnerable children between 5-11 years old.	Israel has vaccinated 68% of its 9.3mn citizens with at least one dose, and 63% are fully vaccinated (majority have received Pfizer). Boosters have been widely administered across age brackets (3.5mn have received a booster), but hesitancy has been more pronounced among younger Arab and ultraorthodox Israelis. Vaccine supply to West Bank and Gaza is making slow progress. More first doses have been administered here in recent weeks: 30% have received a first dose, and the share of fully vaccinated has seen progress at 25%.	Pfizer-BioNTech – Israel administering Pfizer vaccine, in exchange for giving Pfizer extensive patient data. Moderna – 500,000 doses arrived late August in West Bank and Gaza from the US (via COVAX). The Palestinian Authority has received more than 390,000 doses: 100,000 Sinopharm, 97,000 AZ SK Bio, 90,000 Sputnik V, 140,000 Pfizer-BioNTech and 2,000 Moderna, 25,000 AZ SII, and 48,000 AZ R-Pharm.
UAE	UAE has one of the highest immunization rates globally. UAE authorized emergency use of Pfizer and Sputnik booster doses for some groups to be given 6 months after second dose (Abu Dhabi made booster mandatory for anyone vaccinated with Sinopharm).	As of 11 Oct, 20.5mn doses have been administered. 97% of the UAE population has received a first dose, while 86% are fully vaccinated according to the health ministry.	Sinopharm, Sinovac, AZ, Covishield, J&J, Moderna and Pfizer-BioNTech are the WHO-approved vaccines that are accepted. UAE signed an agreement to produce Sinopharm domestically.
Chile	Target to vaccinate 80% of population over 16 years of age has been met. Booster jab campaign began in Aug. Vaccinations for 6-11 age cohort began in late-Sep.	Pfizer vaccinations started in late Dec 2020 but mass campaign using China's Sinovac vaccine started 3 Feb. As of 9 Oct, 15.9mn people (83.3% of population) have received at least one dose, while 14.2mn people (74.3% of the population) have been fully vaccinated. 3.8mn people have received a booster jab since Aug.	Pfizer-BioNTech – agreement for 10mn doses; Sinovac – agreement for 60mn doses over three years; AZ – agreement for 14.4mn doses. COVAX – agreement for 8mn doses. CanSino – agreement for 1.8mn doses. J&J – regulatory clearance in early June. Sputnik V - local regulatory clearance obtained late-Jul.
Hungary	Vaccination is available to all citizens aged 12+ as well as foreigners living in Hungary. There is no official vaccination target. Starting Aug, third vaccine doses were made available to citizens vaccinated four months or more before. The government promotes vaccination mostly rhetorically. The strategy is unlikely to change unless the epidemiological situation shows signs of significant deterioration.	As of 12 Oct, 5.1mn people (60.7% of population) have received at least one jab and 5.7mn (58.4%) have been fully immunized. 911,000 residents (9.3% of population) have received third (booster) dose. Vaccination progress has been extremely slow since midsummer and there are no signs of recovery.	In total, 23.2mn vaccine doses delivered as of 12 Oct. Procurement contracts and deliveries via the EU's joint mechanism: AZ – 6.5mn doses (3.9mn delivered). Moderna – 1.7mn doses (1.7mn delivered). Pfizer-BioNTech – 10.9mn doses (9.mn delivered). J&J – 4.3mn doses (910,800 delivered). National-level procurement: Sputnik V – 2mn doses (2mn delivered). Sinopharm – 5mn doses (5.2mn delivered).
Singapore	Seniors, healthcare, and frontline workers nominated by their employers were the first eligible groups. Starting in Jul, all residents 12 years and older are eligible to be vaccinated. Sinovac has been imported and allowed for distribution by some private clinics but is not being counted in the official vaccination count. Boosters are now available for those above 30.	As of 9 Oct, 4.6mn (80.7% of population) have been fully vaccinated and 0.11mn (1.99% of population) have received at least one dose. Having reached its vaccination targets, Singapore is planning to lift many restrictions and allowing some inbound travel in Q4/2021, especially for vaccinated travelers from selected countries.	Government has concluded agreements with three suppliers, with undisclosed quantities: Pfizer-BioNTech, Moderna and Arcturus. It has received CoronaVac and has allowed private purchases of the vaccine. It is looking for additional supplies in anticipation of possible shortfalls.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Poland	All residents aged 12+ years old are eligible for vaccination. Starting 1 Jul, vaccinated residents can participate in a state-run lottery. Third (booster) vaccine doses are available upon doctor's referral to people with immunodeficiency, healthcare professionals, and people aged 50+. After multiple incidents in the past, security of vaccination sites and staff have been increased.	As of 12 Oct, 19.9mn residents (52.2% of population) received a first jab and 19.6mn (51.4%) are fully vaccinated. Daily vaccination rates remain low but have been slightly recovering since mid-Sept. Around 30% of 80+ year-olds are not vaccinated.	Procurement exclusively via the EU. As of 12 Oct, 67.4mn vaccine doses delivered: 45.8mn Pfizer-BioNTech , 11.5mn AZ , 7.1mn Moderna , 3.2mn J&J .
Greece	Currently offering vaccines to everyone over the age of 12. The summer target of vaccinating 70% of adults was achieved on 30 Sept. Booster jabs were made available to over 60s and those in high-risk groups from 30 Sept. Over 50s can also apply for third shots from mid-Oct.	As of 11 Oct, 60.7% of the total population had received at least one jab and 58.4% are fully vaccinated. Over the last month, most of the jabs carried out have been for second shots as few Greeks have been coming forward over recent weeks to get vaccinated with the first dose.	Greece is using the Pfizer-BioNTech , AZ , Moderna and J&J vaccines, adhering to the EU's procurement process. Next-day appointments for vaccines are available in most parts of the country. Greece has been gifting vaccines to several countries since the summer.
China	The Chinese Centre for Disease Control and Prevention (CDC) said vaccinating 80-85% of the population, or 1.1bn people, is required to reach herd immunity and that this level could be reached by end-2021. The National Health Commission approved booster shots for vulnerable groups, but boosters had not bet begun by 11 Oct.	By 10 Oct, 2.22bn doses (equal to 154% of the population) had been administered. By 28 September, 1.05bn people (73% of the population) were fully vaccinated. Authorities have warned that remaining holdouts are becoming difficult to reach.	Regulators have approved five domestic vaccines; Sinopharm Beijing, Sinopharm Wuhan, CanSino Biologics, Sinovac Biotech, and Anhui Zhifei Longcom Biopharmaceuticals. Fosun Pharmaceutical has contract to distribute and produce Pfizer-BioNTech vaccine and is waiting for mainland regulators to approve.
Saudi Arabia	587+ vaccine centers across the country. Pfizer and AZ administered for free to all residents and citizens. Mix of vaccines approved for two separate doses. Employees can be dismissed from employment for refusal to get vaccinated. Vaccination mandatory to enter commercial and govt spaces (since 1 Aug) and from 10 Oct permits to perform Umrah issued only to vaccinated individuals. From 23 Sept, period of institutional quarantine reduced to 5 days for partially or unvaccinated visitors.	The vaccination program began on 17 Dec. As of 11 Oct, 69% of the population has received at least one dose and 58% are fully vaccinated.	Pfizer-BioNTech, Moderna, J&J, and AZ approved for administration. Sinovac and Sinopharm have just been approved. Sputnik V is not accepted or approved by Saudi Arabia for travelers visiting the Kingdom. KSA signing MoUs in Sept with AZ and Pfizer to manufacture vaccines locally.
Czech Republic	Since 1 Jul, all residents of 12+ years old are eligible for vaccination. The government has set up vaccination centers that allow residents to show up without pre-registering. Third (booster) vaccine dose is available to persons who have received their second/last dose eight months ago or earlier. Government plans to introduce its updated strategy of coping with the pandemic on 14 Oct.	As of 12 Oct, 5.86mn residents (54.8% of population) have received a first jab and 5.76mn (53.8%) were fully immunized. 82.8% of immunizations carried out with Pfizer-BioNTech vaccine; 7.4% with AZ; 7.8% with Moderna and 2.0% with J&J. Vaccine uptake has been consistently declining since mid-Jul, with no improvement in Sept or early Oct. However, vaccination levels are relatively high among key target groups (elderly, healthcare professionals, care home residents).	Procurement has been conducted exclusively via the EU. As of 12 Oct, nearly 16.5mn doses of vaccines delivered: Pfizer-BioNTech – 12.8mn; Moderna – 2.2mn; AZ – 1.1mn; J&J – 350,000.
Turkey	Vaccination program divided into four stages, starting with medical personnel and those over 65, followed by workers in key industries and then the 50-64,18-49 and under 18 age groups, respectively. Turkey originally aimed to vaccinate all adult residents by end-Sept but only 75.1% had been vaccinated by 12 Oct. On 1 Jul, it began offering an additional dose of Pfizer-BioNTech to those who had received two doses of Sinovac, amid concerns about the latter's effectiveness. On 17 Aug, Turkey announced plans to provide a second Pfizer-BioNTech dose to those who had received two doses of Sinovac.	Vaccine rollout started on 13 Jan with Sinovac. On 2 Apr, vaccinations also began with Pfizer-BioNTech vaccine. As of 12 Oct, 112.93mn doses had been administered, with 54.62mn (65.33% of population) people having received a first dose, 46.44mn (55.74% of population) at least two doses and 11.70mn (13.99% of population) three doses. After slowing in May, fresh Pfizer-BioNTech deliveries resulted in a rapid vaccine acceleration from Jun.	Sinovac – agreement for 100mn doses, of which 34.5mn delivered by 12 Oct. Pfizer-BioNTech – agreement for 120mn doses, with 110mn delivered by 12 Oct. Sputnik V – agreement for 50mn doses. 0.4mn doses arrived in late Jun but none had been administered as of 12 Oct. Turkey has not joined COVAX.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Brazil	The National Immunization Plan (PNI) defined the order of vaccination. States have the autonomy to include new categories. Phase 1: health workers; indigenous communities in demarcated territories; over 60s in care institutions; over 75s. Phase 2: 60-74s seniors. Phase 3: adults with comorbidities. Phase 4: education workers, homeless population, security and rescue forces, others. Phase 5: 59-18 gradually. Phase 6: teenagers with comorbidities. Phase 7: teenagers above 12.	As of 12 Oct, 149.2mn first doses have been administered (representing 70.1% of the population), while 99.2mn people (46.5% of population) are fully vaccinated.	AZ – agreement for 179mn by year-end. CoronaVac – 110mn doses by year-end. Pfizer – 200mn by year-end. J&J – 41mn doses expected by year-end. Sputnik V – Contract suspended. Covaxin – Contract suspended. COVAX – minimum 10% of population quota (42mn) doses. WHO provided 14mn doses for distribution until Sept. ButanVac – currently on trial; 100mn expected by year-end.
Argentina	Health sector personnel were first in line for vaccine, followed in descending order by age; security personnel; vulnerable and at-risk in 18-59 age range; education sector; and strategic or vulnerable groups. 12-17 year olds with comorbidities are also receiving vaccines, and regulatory clearance has been given for 3-11 years to be vaccinated with Sinopharm vaccine.	Sputnik V vaccinations started in Dec 2020. As of 12 Oct, 30.2mn people (representing 66.5% of population) have received at least one dose, while 23.9mn people (52.8% of population) are fully vaccinated.	Sputnik V – agreement for 30mn doses; local production underway. AZ – contract for 23.6mn doses, though most to be produced locally in conjunction with Mexico. Sinopharm – agreement for 30mn doses. CanSino – agreement for 5.4mn doses. Pfizer – agreement for 20mn doses. Moderna – 3.5mn doses made available from US government. COVAX – approx. 1.9mn AZ doses delivered; government has been criticized for ordering only 20% of its entitlement.
South Korea	The vaccination campaign, which started in late February, now has a goal of fully vaccinating 70% of the population (with two doses) before November. Everyone aged 16 and above is now eligible, and inoculations start next month for children aged 12 -15. The period between doses has been shortened from Oct.	As of 12 Oct, 59% (30mn people) are fully vaccinated, while 78% (40mn people) have received at least one dose. Almost 1.1mn second shots were administered on 8 October, a new high. Booster shots are now available for certain groups.	Around 195 million doses have been acquired to date, including: Pfizer (67mn); Moderna (40mn); NovaVax (40mn); Astra Zeneca (20mn); Janssen (7.4mn). The government is negotiating with Merck to pre-purchase a forthcoming treatment pill.
Mexico	Frontline medical workers were first in line for a vaccine followed by the over 60s age cohort and then in descending order by age. Government wants all adults to have been offered at least one dose by the end of Oct and plans to have received 150mn vaccine doses by end-2021.	Vaccinations started 24 Dec. Rollout stalled mid-Jan to mid-Feb but subsequently resumed with new vaccines from wider array of suppliers. As of 10 Oct, 66.7mmn people (51.7% of population) have received at least one vaccine dose, with 48.5mn people (37.6% of population) fully inoculated.	AZ – agreement for 77.4mn doses. US has supplied Mexico with 2.7mn additional AZ doses. Pfizer – 34mn doses ordered; 22mn delivered as of 4 Jul. CanSino – 35mn doses agreed. Sputnik V – agreement for 24mn doses, with local production expected soon. COVAX – 51.5mn doses agreed; Sinovac – agreement for 20mn doses. J&J – 1.35mn doses delivered. Sinopharm – agreement for 12mn doses though local regulatory clearance pending. Moderna – local regulatory clearance given in Aug.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Colombia	Plan to vaccinate 70% of the population (35mn people) by end-2021 was reached ahead of schedule in Aug. Medical personnel were first in line, followed by elderly and clinically vulnerable. Booster shot campaign for over 70s who received their original dose over six months ago started in Oct.	Vaccination campaign started on 17 Feb with Pfizer vaccine. As of 9 Oct, 24.4mn people (47.8% of the population) have received at least one dose, while 18.5mn people (36.4% of the population) are fully vaccinated (3.5mn of these received a single dose J&J vaccine).	Pfizer-BioNTech – agreement for 15mn doses. AZ – 10mn doses agreed. J&J – agreement for 9mn doses. Sinovac – agreement for 10mn doses. Moderna – agreement for 10mn doses. COVAX – agreement for 20mn doses.
Taiwan	Latest delivery of Pfizer-BioNTech will be offered to all those aged 45 and over. Latest round of AZ offered to those aged 18 and over who received first dose.	As of 8 Oct, 4.2mn people (18% of the population) was fully vaccinated and a further or 9.5mn (40% of the population) had received one dose. Average daily pace (7-day moving average) was 230,000 doses on 8 Oct (1% of population per day), down from peak of 305,000 on 1 Oct but still higher than most of the Jun-Sept period.	23.6mn doses received by 8 Oct, which 17.5mn already administered. Further 57mn doses ordered but not yet delivered. AZ is largest supplier, followed by Moderna and Pfizer-BioNTech. Taiwan-developed Medigen vaccine was approved for emergency use in July, and phase 3 trials are in progress in Paraguay.
Malaysia	Malaysia is in the third phase of its vaccination program, where anyone above 12 years old is eligible to receive a shot.	As of 10 Oct, 21.44mn (67.1% of population) have been fully vaccinated and another 3.1mn (9.6%) are still on their first shot.	Pfizer-BioNTech – 32mn doses; Sinovac – 12mn doses; AZ – 6.4mn doses via COVAX facility and another 6.4mn contracted directly; Sputnik V – 6.4mn doses; CanSino Biologics – 3.5mn doses
India	With around 19.2% of the population fully vaccinated as of 9 Oct and 48.8% having received at least one jab, the strategy now is to accelerate vaccinations while ensuring infection rates are contained. All vaccinations in government facilities are free of cost and children above 12 are also being vaccinated. Most public areas across India – schools, places of worship, sports facilities, theatres, and cinemas and eating places – are now open with only social distancing and mask restrictions.	Both death rates and infections rates are declining. However, amid the three-month festival season that started in Oct, the govt is taking no chances: new oxygen plants have already been readied and hospitals have special mandates to quickly process and admit infected patients. "Mission 100 Days" underway to contain and prevent infection until Christmas. Govt closely is watching world developments and has not ruled out booster doses.	Export ban lifted for vaccine exports to many neighboring countries. India will export to Bangladesh, Nepal, Myanmar and Iran. Covishield vaccines also to be exported to the UK. All vaccines certified safe in country of origin allowed for import duty free. India will celebrate 1bn vaccinations mid-Oct. Currently, Covishield, Covaxin and Sputnik are in use. A new Covid-19 vaccine that uses circular strands of DNA to prime the immune system against the virus SARS-CoV-2 has been approved and might begin to be used in Nov.
Russia	Vaccination available to all citizens 18+. With infections and death levels remaining at all-time highs, an increasing number of federal subjects (regions) are introducing some form of compulsory vaccination. Also, most Covid-19 restrictions target non-vaccinated residents.	Vaccinations started in early Dec As of 12 Oct, an estimated 49.7mn residents (34% of population) had received at least one jab and 45.1mn (30% of population) were fully vaccinated. The pace of new vaccinations is expected to surge in Oct and early Nov as an increasing number of the country's regions are rolling out compulsory vaccination schemes.	Russia relies solely on domestically developed vaccines: Sputnik V, EpiVac, CoviVac and Sputnik Light. A fifth domestic vaccine EpiVacCorona-N – which is an updated version of EpiVac – has been registered by the Ministry of Health in late Aug. To encourage vaccination, the health ministry is considering limited imports of non-Russian vaccines.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Peru	Nov 2020 political crisis interrupted vaccine procurement process, but caretaker government that left office end-July accelerated procurement; in total, government has contracts for 63mn doses in place for 2021 in addition to further agreements in pipeline. Booster jabs for medical personnel from Oct.	Vaccinations using Sinopharm vaccine started 9 Feb. Pfizer-and AZ vaccines also being administered. As of 9 Oct, 16.8mn people (representing 50.3% of the population) have received at least one dose. 12.7mn people (38.1% of population) have received two doses.	Sinopharm – contract for 38mn doses. AZ – agreement for 14.4mn doses. Pfizer-BioNTech – original agreement for 20mn doses expanded to 35mn doses. COVAX – agreement for 13.2mn doses Moderna – 20mn doses agreed to be delivered in 2022. Sputnik – agreement for 20mn doses but deliveries not expected until 2022.
Thailand	All adults and children above 12 are eligible for vaccination. However, there are two special cases – companies will be allowed to import and distribute vaccines, and tourism areas such as Phuket are being prioritized.	Uneven supplies of locally-produced AZ vaccines sometimes slow down vaccine rollout. Sinovac and Sinopharm vaccines are now being imported. As of 10 Oct, 23.05mn (33.11%) of population have been fully vaccinated and 11.7mn (16.8%) are on their first jab.	Sinovac – 2mn, but Thailand is negotiating for an additional 6mn doses. AZ – 61mn (imported and local joint venture). Sinopharm - 6mn doses through private sector importation
Indonesia	All adults and children above 12 are eligible for vaccination. Vaccines procured by central government; distributed for free but not mandatory. Government is allowing the private sector to purchase vaccines for their employees, with these vaccinations now underway. Boosters are being given to healthcare workers but not yet the general population.	As of 10 Oct, 57.6mn (21.3% of the population) have been fully vaccinated and another 42.7mn (15.8%) are on their first jab. Vaccine supplies are sufficient, but the immunization program is slowing down due to what appears to be vaccine hesitation among the remaining population.	Sinovac – 125mn doses; Pfizer-BioNTech – 100mn doses; Novavax – 100mn doses; COVAX initiative – 100mn doses; AZ – 100mn doses; private sector importation unknown.
Pakistan	Covid-19 infections are coming down, with a seven-day average of new cases of < 1,200, or 20% of the peak caseload reached in Jun. There have been 1,25mn infections and 28,000 coronavirus-related deaths reported in the country since the pandemic began. Vaccinations are now permitted for 12-year olds and above. Govt has imposed stiff restrictions for unvaccinated people - those without two vaccines will be unable to enter domestic flights, shops, and restaurants.	As of 7 Oct, 14.5% of the population had been fully vaccinated, while 28% of population had received at least one dose.	Pfizer-BioNTech, SII-AstraZeneca (COVISHIELD) vaccine, Moderna and Sinopharm are in use via the UN-administered COVAX network. The country has a target of vaccinating 70mn people by the end of 2021. Emergency assistance amounting to USD 500mn from the Asian Development Bank is expected to finance the ongoing vaccination procurement as Pakistan faces funding problems.
South Africa	Plans to vaccinate 35mn people by end-2021 and 40mn by Mar 2022. Rollout started late (18 Feb) but is advancing amid vastly improved vaccine supply. Age-group-based rollout largely abandoned.	J&J and Pfizer vaccines are arriving in large quantities. Vaccination open to all adults (registration for 18-34 age cohort began on 20 Aug). Shots administered now average around 240,000 per day but official target revised upwards to 300,000. As of 10 Oct, 13.5mn people (representing 22.4% of population) have received at least one dose, while 9.9mn people (16.5% of population) are fully vaccinated.	Initially reliant on COVAX/AZ vaccines, South Africa pivoted to two manufacturers, J&J and Pfizer. Large-scale deliveries began in May. J&J - 31mn doses Pfizer-BioNTech - 30mn doses Authorities now reconsidering acquiring other vaccines, including AZ. South Africa is also setting itself up as a production hub of J&J (and soon Pfizer) vaccines.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Philippines	Vaccine rollout started in Mar with high-risk groups such as healthcare workers; workers in education, social welfare agencies; law enforcement and military personnel; the poor; senior citizens; other vulnerable populations. Private sector allowed to import vaccines, though some are required to make counterpart donations. Vaccinations are now being considered for teenagers. Metro Manila and urban centers have been the priority for vaccine deployment, resulting in vaccination rates being higher in these areas.	As of 11 Oct, 23.4mn (21.6%) of the population are fully vaccinated and 3.5mn (3.1%) are fully vaccinated. Shortages in supply early in the third quarter have been addressed but the vaccination rate has dropped due to hesitancy and the uneven availability of health care workers. This has made more uncertain the government's goal of reaching 80% of the target population by mid-2022.	The Philippine government has ordered 113mn doses from five vaccine manufacturers: Sinovac – 26mn doses, Sputnik V – 10mn, Moderna – 20mn, AZ – 17mn, Pfizer – 40mn. Several million Novavax doses imported by the private sector are expected in Q4/2021.
Egypt	Walk-in vaccinations now being offered at youth centers across the country without prior registration to help relieve pressure on hospitals and health units amid a fourth wave. There are now 1,100 vaccination centers across Egypt and more than 1,300 mobile teams nationwide as part of the "Together We Are Assured" campaign that was launched after complaints of long wait times to get vaccines. Govt announced in Aug plans to vaccinate all 4.5mn state employees within two months in addition to workers in preuniversity education, university employees, and students.	As of 11 Oct, Egypt has administered 20.1mn doses; 13% of the population has received a first dose, while only 6.6% are fully vaccinated. Egypt aims to vaccinate 40% by Dec; 70% by 2022 but as been falling behind on targets to date. Egypt's VACSERA complex aims to produce 8 types of vaccines and serve as a vaccine hub and the largest producer of Covid-19 vaccines in MENA.	COVAX – advanced purchase agreement for 40mn doses to be provided in batches. J&J – contract to buy 20mn doses; delivery of 261,600 doses arrived in Aug, second shipment in Sept. Sinopharm – agreement for 40mn doses. Pfizer-BioNTech – contracts reportedly signed for 20mn. 5.2mn doses of Pfizer and Moderna arrived Sept. Egypt now in talks with Moderna to manufacture the vaccine locally. AZ – agreement for 30mn doses; 1.7mn doses arrived early Aug via COVAX, UK sent addtl 300k early Aug (via COVAX) plus another 300,000 doses in mid-Aug. Sputnik V – 25mn have been secured. Egypt signed agreements to manufacture Sputnik V and Sinovac vaccines domestically; production of 15mn doses of Sinovac locally.
Kenya	Kenya now plans to vaccinate 10mn adults by Dec, and all adults by Jun 2022. Rollout in three phases (which may overlap): 1) frontline workers (including healthcare, teachers, army/police officers) and people aged 58+; 2) frontline workers and adults aged 18+ with comorbidities; 3) all adults aged 18+.	Rollout began 5 Mar with first 1mn AZ/COVAX doses, but supplies ran out by Jun amid India's export restrictions. Deliveries picked up in Jul via COVAX deliveries and donations (mainly from the US and EU). As of 9 Oct, 3.1mn people (5.7% of population) had received at least one dose, while 1mn people (1.9% of population) were fully vaccinated.	Kenya relies on COVAX for 24mn doses but recently budgeted for additional vaccine purchases. AZ, Pfizer and Moderna donations arriving from various countries; Sinopharm vaccines also expected. 13mn J&J vaccines ordered under the African Vaccine Acquisition Task Team (AVATT) initiative are being delivered gradually.
Nigeria	Vaccination targets: 40% of population in 2021, 70% by end-2022. Healthcare personnel; people over 50; people with underlying health conditions to be prioritized. Most heavily affected states prioritized in allocation of doses.	First vaccine deliveries since Mar arrived in Aug, including 4mn doses of Moderna and 700,000 AZ vaccines from respective US and UK stockpiles via COVAX. Delivery of 7.7mn Sinopharm vaccines via COVAX expected, date tbc. First small batch (178,000) of the J&J vaccine procured via AVATT arrived in Aug, monthly deliveries via AVATT expected to follow until 29.8mn doses have been supplied. Another 500,000 AZ vaccines from French stockpiles arrived in early Oct. As of 8 Oct, 2.35% of population had received at least one jab and 1.02% were fully vaccinated.	20% of vaccines supposed to be supplied through the COVAX initiative. Government expects total of 58mn vaccine doses from COVAX (16mn) and the AVATT (42mn). Government also expressed interest in procuring Sputnik V and/or Sinovac/Sinopharm vaccines.

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.